.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 6,670,351

« Back to Dashboard

Claims for Patent: 6,670,351

Title: Method for ameliorating muscle weakness/wasting in a patient infected with human immunodeficiency virus-type 1
Abstract:A method for attenuating the HIV-associated myopathy and muscle wasting associated with infection by human immunodeficiency virus-Type 1. Administration of oxandrolone in a daily dosage of about 2.5 to about 20 milligrams is described.
Inventor(s): Berger; Joseph R. (Miami, FL)
Assignee: Bio-Technology General Corporation (Iselin, NJ)
Application Number:09/469,817
Patent Claims: 1. A method for ameliorating HIV-associated myopathy and muscle wasting in an AIDS patient which comprises administering a therapeutically effective amount of oxandrolone to the AIDS patient.

2. The method in accordance with claim 1 wherein the therapeutically effective amount comprises a daily dosage of between about 2.5 to about 30 milligrams.

3. The method in accordance with claim 1 wherein the therapeutically effective amount comprises a daily dosage of between about 2.5 to about 20 milligrams.

4. The method in accordance with claim 3 wherein the daily dosage is about 20 milligrams.

5. The method in accordance with claim 3 wherein the daily dosage is about 15 milligrams.

6. The method in accordance with claim 1 wherein the oxandrolone is administered orally.

7. The method in accordance with claim 6 wherein the oxandrolone is administered in the form of a tablet.

8. The method in accordance with claim 2 wherein the oxandrolone is administered orally.

9. The method in accordance with claim 8 wherein the oxandrolone is administered in the form of a tablet.

10. The method in accordance with claim 3 wherein the oxandrolone is administered orally.

11. The method in accordance with claim 10 wherein the oxandrolone is administered in the form of a tablet.

12. The method in accordance with claim 4 wherein the oxandrolone is administered orally.

13. The method in accordance with claim 12 wherein the oxandrolone is administered in the form of a tablet.

14. The method in accordance with claim 5 wherein the oxandrolone is administered orally.

15. The method in accordance with claim 14 wherein the oxandrolone is administered in the form of a tablet.

16. The method in accordance with claim 1 wherein the oxandrolone is administered daily for a time period in the range of about two weeks to about six months.

17. The method in accordance with claim 6 wherein the oxandrolone is administered daily for a time period in the range of about two weeks to about six months.

18. The method in accordance with claim 8 wherein the oxandrolone is administered daily for a time period in the range of about two weeks to about six months.

19. The method in accordance with claim 10 wherein the oxandrolone is administered daily for a time period in the range of about two weeks to about six months.

20. The method in accordance with claim 12 wherein the oxandrolone is administered daily for a time period in the range of about two weeks to about six months.

21. The method in accordance with claim 14 wherein the oxandrolone is administered daily for a time period in the range of about two weeks to about six months.

22. The method in accordance with claim 1 wherein the oxandrolone is administered percutaneously.

23. The method in accordance with claim 1 wherein the oxandrolone is administered intravenously.

24. The method in accordance with claim 1 wherein the oxandrolone is administered intramuscularly.

25. The method in accordance with claim 1 wherein the oxandrolone is administered sublingually.

26. The method in accordance with claim 1 wherein the oxandrolone is administered transdermally.

27. The method in accordance with claim 1 wherein the oxandrolone is administered in a unit dose of about 2 to about 5 milligrams three times daily.

28. The method in accordance with claim 2 wherein the oxandrolone is administered in a unit dose of about 2 to about 5 milligrams three times daily.

29. The method in accordance with claim 3 wherein the oxandrolone is administered in a unit dose of about 2 to about 5 milligrams three times daily.

30. The method in accordance with claim 4 wherein the oxandrolone is administered in a unit dose of about 2 to about 5 milligrams three times daily.

31. The method in accordance with claim 5 wherein the oxandrolone is administered in a unit dose of about 2 to about 5 milligrams three times daily.

32. The method in accordance with claim 1 wherein the oxandrolone is administered in a unit dose of about 1 to about 5 milligrams three or four times daily.

33. The method in accordance with claim 2 wherein the oxandrolone is administered in a unit dose of about 1 to about 5 milligrams three or four times daily.

34. The method in accordance with claim 3 wherein the oxandrolone is administered in a unit dose of about 1 to about 5 milligrams three or four times daily.

35. The method in accordance with claim 4 wherein the oxandrolone is administered in a unit dose of about 1 to about 5 milligrams three or four times daily.

36. The method in accordance with claim 5 wherein the oxandrolone is administered in a unit dose of about 1 to about 5 milligrams three or four times daily.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc